Your browser is no longer supported. Please, upgrade your browser.
CKPT Checkpoint Therapeutics, Inc. daily Stock Chart
Checkpoint Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.10 Insider Own1.10% Shs Outstand29.63M Perf Week-10.21%
Market Cap88.59M Forward P/E- EPS next Y-1.08 Insider Trans- Shs Float19.07M Perf Month-34.29%
Income-27.30M PEG- EPS next Q-0.23 Inst Own2.70% Short Float3.72% Perf Quarter15.89%
Sales1.20M P/S73.83 EPS this Y3.80% Inst Trans1.91% Short Ratio4.45 Perf Half Y-27.78%
Book/sh0.77 P/B3.88 EPS next Y-5.90% ROA-96.90% Target Price15.50 Perf Year-55.37%
Cash/sh0.96 P/C3.13 EPS next 5Y- ROE-126.70% 52W Range2.22 - 7.38 Perf YTD-22.94%
Dividend- P/FCF- EPS past 5Y- ROI-151.80% 52W High-59.49% Beta-
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low34.68% ATR0.37
Employees6 Current Ratio4.40 Sales Q/Q-75.00% Oper. Margin- RSI (14)37.05 Volatility7.60% 10.05%
OptionableNo Debt/Eq0.00 EPS Q/Q19.40% Profit Margin- Rel Volume0.11 Prev Close2.76
ShortableYes LT Debt/Eq0.00 EarningsAug 08 Payout- Avg Volume159.51K Price2.99
Recom1.50 SMA20-19.63% SMA50-20.14% SMA200-19.80% Volume17,385 Change8.33%
Dec-08-17Initiated H.C. Wainwright Buy $11
Oct-09-18 01:54PM  Do Institutions Own Shares In Checkpoint Therapeutics Inc (NASDAQ:CKPT)? Simply Wall St. -9.34%
Sep-27-18 08:00AM  Checkpoint Therapeutics to Present at Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-25-18 08:00AM  Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101 GlobeNewswire -19.12%
Sep-07-18 12:25PM  CKPT: Second Mover Could Have First Class Advantage Zacks Small Cap Research
Sep-06-18 07:30AM  Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101 GlobeNewswire -11.11%
Aug-30-18 08:00AM  Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire +6.02%
Aug-13-18 10:30AM  CKPT: CK-101 Data Announced Zacks Small Cap Research
08:00AM  Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer GlobeNewswire
Aug-08-18 07:30AM  Checkpoint Therapeutics, Inc. (CKPT) Reports Q2 Loss, Misses Revenue Estimates Zacks -5.34%
Aug-07-18 04:30PM  Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire +6.50%
Aug-02-18 10:29AM  Special Report: Biotech incubator taps investors through in-house brokerage Reuters +5.06%
Jun-28-18 10:25AM  CKPT: Checkpoint Inhibitors: Dominating the Immuno-Oncology Space Zacks Small Cap Research
Jun-04-18 08:00AM  Checkpoint Therapeutics to Participate in June Investor Conferences GlobeNewswire
May-10-18 04:30PM  Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Apr-18-18 09:00AM  Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-05-18 08:38AM  Why Checkpoint Therapeutics (CKPT) Might Be a Diamond in the Rough Zacks
Mar-21-18 08:00AM  Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301 GlobeNewswire
Mar-19-18 07:40AM  Blog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR Meeting ACCESSWIRE
Mar-15-18 04:05PM  Checkpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
07:30AM  Checkpoint Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-13-18 07:45AM  Checkpoint Therapeutics to Participate in March Investor Conferences GlobeNewswire
Mar-08-18 09:00AM  Checkpoint Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire -11.99%
Mar-07-18 04:05PM  Checkpoint Therapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-06-18 08:30AM  Checkpoint Therapeutics to Present at BIO CEO & Investor Conference GlobeNewswire
Jan-03-18 07:30AM  Checkpoint Therapeutics to Present at Biotech Showcase 2018 GlobeNewswire -6.48%
Dec-14-17 07:30AM  Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 10, 2018 GlobeNewswire -6.72%
Dec-08-17 10:42AM  Checkpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together' Benzinga +21.26%
Dec-06-17 02:20PM  CKPT: A Smokin Opportunity in PD-L1 Therapy and Beyond Zacks Small Cap Research +13.86%
Oct-05-17 09:00AM  Checkpoint Therapeutics (CKPT) Starts CK-301 Trials Zacks Small Cap Research -10.91%
07:30AM  Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301 GlobeNewswire
Sep-20-17 08:00AM  Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire
Sep-12-17 11:00AM  Checkpoint Inhibitors Are Hot, and CKPT Has Something in the Oven Zacks Small Cap Research -5.06%
Sep-11-17 08:30AM  Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer GlobeNewswire
Sep-05-17 08:00AM  Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Jul-28-17 10:00AM  Checkpoint (CKPT): An Innovator of Immune-Enhanced Combination Therapies in Solid Tumors Zacks Small Cap Research
Jun-26-17 08:00AM  Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market GlobeNewswire
Feb-28-17 07:00AM  Checkpoint Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CKPT-US : February 28, 2017 Capital Cube +42.86%
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC. Its pipeline consists of glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.